Understanding the functional role of Immune-related Intercellular Signalling Networks during tissue Development and Cancer
This project aims to uncover immune-related intercellular crosstalk in tissue development and cancer using single-cell RNA-sequencing and functional assays to identify novel therapeutic targets.
Projectdetails
Introduction
Intercellular signalling networks drive fundamental tissue processes. Immune cells present a wide range of versatile functions and distinctive plasticity, which position them as tissue signalling hubs during tissue development, homeostasis, and cancer. Recent genomic advances have greatly improved our understanding of cell composition and states; however, investigation of the molecular signatures of intercellular crosstalk at the single-cell level remains limited.
Research Objectives
Exploring tissue development, homeostasis, and cancer from the point of view of immune-controlled signalling networks has the potential to reveal novel therapeutic candidates with high biological and medical impact. By applying functional assays alongside novel single-cell RNA-sequencing technologies and computational approaches, such as physically interacting-cell sequencing (PIC-seq), I propose to crack the functional consequences of the whole-tissue signalling networks to revisit key developmental and cancer immunology questions:
-
What immune-related intercellular crosstalk drives tissue development and cancer?
We will integrate scRNA-seq and PIC-seq analysis along mouse lung, liver, and kidney development, and human carcinomas. We will apply large-scale comparative cross-tissue and cross-species analysis, ex-vivo and in-vivo studies, to identify tissue-exclusive and shared signalling during tissue physiology or cancer. -
What can we study on tumor-escape mechanisms, based on physiological signalling networks?
We will perform development versus cancer large-scale molecular comparisons, in-vivo cancer models for functional perturbations, and clinical validations to identify novel immunotherapy targets.
Expected Outcomes
Successful completion of the project will reveal novel cancer and developmental immunotherapy targets. Concomitantly, findings will comprise a valuable resource for tissue-molecular signalling and will generate a platform for investigating biological enigmas by elucidating the consequences of cellular communication.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.025.000 |
Totale projectbegroting | € 2.025.000 |
Tijdlijn
Startdatum | 1-4-2022 |
Einddatum | 31-3-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TEL AVIV UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Elucidating the networks of immune stromal connections by Perturbation of Immunity in Cancer - towards developing novel therapeutic strategiesThis project aims to map immune and stromal cell interactions in the tumor microenvironment to develop targeted therapies that enhance immunotherapy efficacy against cancer. | ERC Starting... | € 1.500.000 | 2025 | Details |
Architecture of Peripheral Neuroimmune Circuits and SynapsesThis project aims to explore neuro-ILC2 interactions in vivo using innovative labelling tools to enhance understanding of neuroimmune dynamics and their implications for tissue health and disease. | ERC Advanced... | € 3.500.000 | 2024 | Details |
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapiesThe TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies. | ERC Advanced... | € 2.500.000 | 2022 | Details |
Spatial Quantification of Cellular Metabolism in the Tumor Immune MicroenvironmentThis project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment. | ERC Starting... | € 1.497.756 | 2023 | Details |
Integrated Mechanistic Modelling and Analysis of Large-scale Biomedical DataINTEGRATE aims to enhance cancer treatment by developing advanced computational models that integrate patient-derived data for improved drug targeting and clinical trial planning. | ERC Consolid... | € 1.854.546 | 2024 | Details |
Elucidating the networks of immune stromal connections by Perturbation of Immunity in Cancer - towards developing novel therapeutic strategies
This project aims to map immune and stromal cell interactions in the tumor microenvironment to develop targeted therapies that enhance immunotherapy efficacy against cancer.
Architecture of Peripheral Neuroimmune Circuits and Synapses
This project aims to explore neuro-ILC2 interactions in vivo using innovative labelling tools to enhance understanding of neuroimmune dynamics and their implications for tissue health and disease.
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies
The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.
Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment
This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.
Integrated Mechanistic Modelling and Analysis of Large-scale Biomedical Data
INTEGRATE aims to enhance cancer treatment by developing advanced computational models that integrate patient-derived data for improved drug targeting and clinical trial planning.